Association between mitochondrial dysfunction and hepatocellular carcinoma

Xiaoqiang GAO; Shi ZUO; Xiaodong JIA; Yinying LU

doi:10.3969/j.issn.1001-5256.2022.06.045

Volume 38 Issue 6

Jun. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(6): 1436-1439

PDF( 2104 KB)

Association between mitochondrial dysfunction and hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.06.045

Xiaoqiang GAO^{1, 2},
Shi ZUO¹,
Xiaodong JIA²,
Yinying LU^{2
,
,
,}

1.
Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
2.
Comprehensive Liver Cancer Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

Research funding:

General Projects of Beijing Natural Science Foundation (7212099);

Special Sustainable Development Project of Shenzhen Science and Technology Innovation Committee (2019N002);

National Natural Science Foundation of China (81902495);

Support Project of PLA General Hospital (QNF19040)

More Information

Corresponding author: LU Yinying, luyinying1973@163.com (ORCID: 0000-0002-7737-2334)
Received Date: 2021-09-23
Accepted Date: 2021-10-26
Published Date: 2022-06-20

Abstract

Abstract

Hepatocellular carcinoma (HCC) is a type of tumor with a high incidence rate, a low rate of early diagnosis, and poor prognosis, and its development and progression involve many factors. As an important organelle in cells, mitochondria is the "energy factory" of cells and is one of the main sites for the production of reactive oxygen species in vivo, and it also participates in the regulation of cell apoptosis. There are varying degrees of changes in mitochondrial membrane, oxidation respiratory chain, mitochondrial dynamics, mitochondrial DNA, and mitochondrial calcium homeostasis during the development and progression of HCC, and such changes may affect the progression of HCC. This article systematically elaborates on the association between mitochondria and HCC, so as to provide a new direction for the diagnosis and treatment of HCC.
- Mitochondrion,
- Carcinoma, Hepatocellular,
- Therapeutics

FullText(HTML)

References(38)

References

[1]	LOOSEN SH, CASTOLDI M, JÖRDENS MS, et al. Serum levels of circulating microRNA-107 are elevated in patients with early-stage HCC[J]. PLoS One, 2021, 16(3): e0247917. DOI: 10.1371/journal.pone.0247917.
[2]	GAO Y, LYU L, FENG Y, et al. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents[J]. Int J Med Sci, 2021, 18(14): 3066-3081. DOI: 10.7150/ijms.59930.
[3]	XING M, WANG X, KIKEN RA, et al. Immunodiagnostic biomarkers for hepatocellular carcinoma (HCC): The first step in detection and treatment[J]. Int J Mol Sci, 2021, 22(11) : 6139. DOI: 10.3390/ijms22116139.
[4]	SUPINSKI GS, SCHRODER EA, CALLAHAN LA. Mitochondria and critical illness[J]. Chest, 2020, 157(2): 310-322. DOI: 10.1016/j.chest.2019.08.2182.
[5]	MIDDLETON P, VERGIS N. Mitochondrial dysfunction and liver disease: Role, relevance, and potential for therapeutic modulation[J]. Therap Adv Gastroenterol, 2021, 14: 17562848211031394. DOI: 10.1177/17562848211031394.
[6]	LIAO ZB, TAN XL, DONG KS, et al. miRNA-448 inhibits cell growth by targeting BCL-2 in hepatocellular carcinoma[J]. Dig Liver Dis, 2019, 51(5): 703-711. DOI: 10.1016/j.dld.2018.09.021.
[7]	YIN PH, LEE HC, CHAU GY, et al. Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma[J]. Br J Cancer, 2004, 90(12): 2390-2396. DOI: 10.1038/sj.bjc.6601838.
[8]	HERNÁNDEZ-ALVAREZ MI, ZORZANO A. Mitochondrial dynamics and liver cancer[J]. Cancers (Basel), 2021, 13(11): 2571. DOI: 10.3390/cancers13112571.
[9]	LI Y, GUO X, GUO S, et al. Next generation sequencing-based analysis of mitochondrial DNA characteristics in plasma extracellular vesicles of patients with hepatocellular carcinoma[J]. Oncol Lett, 2020, 20(3): 2820-2828. DOI: 10.3892/ol.2020.11831.
[10]	JIN M, WANG J, JI X, et al. MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 136. DOI: 10.1186/s13046-019-1135-x.
[11]	SUN H, YU J, WEN Z, et al. Decreased expression of Beclin-1 in patients with hepatocellular carcinoma[J]. J BUON, 2019, 24(2): 634-641.
[12]	FUNK K, CZAUDERNA C, KLESSE R, et al. BAX redistribution induces apoptosis resistance and selective stress sensitivity in human HCC[J]. Cancers (Basel), 2020, 12(6) : 1437. DOI: 10.3390/cancers12061437.
[13]	LE PH, HUANG SC, LIM SN, et al. Complex Ⅳ subunit 1 defect predicts postoperative survival in hepatocellular carcinoma[J]. Oncol Lett, 2014, 7(5): 1430-1438. DOI: 10.3892/ol.2014.1966.
[14]	XIAO MH, LIN YF, XIE PP, et al. Downregulation of a mitochondrial micropeptide, MPM, promotes hepatoma metastasis by enhancing mitochondrial complex I activity[J]. Mol Ther, 2022, 30(2): 714-725. DOI: 10.1016/j.ymthe.2021.08.032.
[15]	WANG T, XIE X, LIU H, et al. Pyridine nucleotide-disulphide oxidoreductase domain 2 (PYROXD2): Role in mitochondrial function[J]. Mitochondrion, 2019, 47: 114-124. DOI: 10.1016/j.mito.2019.05.007.
[16]	LI Y, LIN S, LI L, et al. PDSS2 Deficiency Induces hepatocarcinogenesis by decreasing mitochondrial respiration and reprogramming glucose metabolism[J]. Cancer Res, 2018, 78(16): 4471-4481. DOI: 10.1158/0008-5472.CAN-17-2172.
[17]	ZHANG Z, LI TE, CHEN M, et al. MFN1-dependent alteration of mitochondrial dynamics drives hepatocellular carcinoma metastasis by glucose metabolic reprogramming[J]. Br J Cancer, 2020, 122(2): 209-220. DOI: 10.1038/s41416-019-0658-4.
[18]	WANG X, LIU Y, SUN J, et al. Mitofusin-2 acts as biomarker for predicting poor prognosis in hepatitis B virus related hepatocellular carcinoma[J]. Infect Agent Cancer, 2018, 13: 36. DOI: 10.1186/s13027-018-0212-7.
[19]	ANDERSON S, BANKIER AT, BARRELL BG, et al. Sequence and organization of the human mitochondrial genome[J]. Nature, 1981, 290(5806): 457-465. DOI: 10.1038/290457a0.
[20]	GUO ZS, JIN CL, YAO ZJ, et al. Analysis of the mitochondrial 4977 bp deletion in patients with hepatocellular carcinoma[J]. Balkan J Med Genet, 2017, 20(1): 81-86. DOI: 10.1515/bjmg-2017-0006.
[21]	HUNG WY, LIN JC, LEE LM, et al. Tandem duplication/triplication correlated with poly-cytosine stretch variation in human mitochondrial DNA D-loop region[J]. Mutagenesis, 2008, 23(2): 137-142. DOI: 10.1093/mutage/gen002.
[22]	HIGURASHI M, MARUYAMA T, NOGAMI Y, et al. High expression of FOXM1 critical for sustaining cell proliferation in mitochondrial DNA-less liver cancer cells[J]. Exp Cell Res, 2020, 389(1): 111889. DOI: 10.1016/j.yexcr.2020.111889.
[23]	ROMERO-GARCIA S, PRADO-GARCIA H. Mitochondrial calcium: Transport and modulation of cellular processes in homeostasis and cancer (Review)[J]. Int J Oncol, 2019, 54(4): 1155-1167. DOI: 10.3892/ijo.2019.4696.
[24]	LI CJ, LIN HY, KO CJ, et al. A novel biomarker driving poor-prognosis liver cancer: overexpression of the mitochondrial calcium gatekeepers[J]. Biomedicines, 2020, 8(11): 451. DOI: 10.3390/biomedicines8110451.
[25]	KOIKE K. Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: Lessons from animal model studies[J]. Clin Gastroenterol Hepatol, 2005, 3(10 Suppl 2): S132-S135. DOI: 10.1016/s1542-3565(05)00700-7.
[26]	ZHANG R, ZHANG F, WANG C, et al. Identification of sequence polymorphism in the D-Loop region of mitochondrial DNA as a risk factor for hepatocellular carcinoma with distinct etiology[J]. J Exp Clin Cancer Res, 2010, 29: 130. DOI: 10.1186/1756-9966-29-130.
[27]	JIN Y, YU Q, ZHOU D, et al. The mitochondrial DNA 9-bp deletion polymorphism is a risk factor for hepatocellular carcinoma in the Chinese population[J]. Genet Test Mol Biomarkers, 2012, 16(5): 330-334. DOI: 10.1089/gtmb.2011.0208.
[28]	AHMED HS, WAHAB EA, ELHADY HA, et al. Association of genetic polymorphism of BCL-2 (rs2279115) with susceptibility to HCV-related hepatocellular carcinoma[J]. Immunol Res, 2020, 68(4): 189-197. DOI: 10.1007/s12026-020-09143-7.
[29]	HUANG Q, ZHAN L, CAO H, et al. Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways[J]. Autophagy, 2016, 12(6): 999-1014. DOI: 10.1080/15548627.2016.1166318.
[30]	REN T, ZHANG H, WANG J, et al. MCU-dependent mitochondrial Ca²⁺ inhibits NAD⁺/SIRT3/SOD2 pathway to promote ROS production and metastasis of HCC cells[J]. Oncogene, 2017, 36(42): 5897-5909. DOI: 10.1038/onc.2017.167.
[31]	HU W, FU J, LU SX, et al. Decrease of Bcl-xL/Bcl-2-associated death promoter in hepatocellular carcinoma indicates poor prognosis[J]. Am J Cancer Res, 2015, 5(5): 1805-1813.
[32]	LI S, WAN P, PENG T, et al. Associations between sequence variations in the mitochondrial DNA D-loop region and outcome of hepatocellular carcinoma[J]. Oncol Lett, 2016, 11(6): 3723-3728. DOI: 10.3892/ol.2016.4466.
[33]	JIAN C, FU J, CHENG X, et al. Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis[J]. Cell Metab, 2020, 31(5): 892-908. e11. DOI: 10.1016/j.cmet.2020.04.011.
[34]	CHIOU JF, TAI CJ, WANG YH, et al. Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism[J]. Cancer Biol Ther, 2009, 8(20): 1904-1913. DOI: 10.4161/cbt.8.20.9436.
[35]	LI Y, XIA J, SHAO F, et al. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis[J]. Biochem Biophys Res Commun, 2021, 534: 877-884. DOI: 10.1016/j.bbrc.2020.10.083.
[36]	ZHANG C, HU J, SHENG L, et al. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation[J]. Toxicol Appl Pharmacol, 2019, 365: 51-60. DOI: 10.1016/j.taap.2019.01.004.
[37]	YE RR, PENG W, CHEN BC, et al. Mitochondria-targeted artesunate conjugated cyclometalated iridium(iii) complexes as potent anti-HepG2 hepatocellular carcinoma agents[J]. Metallomics, 2020, 12(7): 1131-1141. DOI: 10.1039/d0mt00060d.
[38]	PITTALA S, KRELIN Y, SHOSHAN-BARMATZ V. Targeting liver cancer and associated pathologies in mice with a mitochondrial VDAC1-based peptide[J]. Neoplasia, 2018, 20(6): 594-609. DOI: 10.1016/j.neo.2018.02.012.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (582) PDF downloads(62)

Association between mitochondrial dysfunction and hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.06.045

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Association between mitochondrial dysfunction and hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.06.045

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content